Report cover image

Uveal Melanoma Drug Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20146958

Description

Uveal melanoma ranks as the most common type of intraocular tumor in adults globally, with its metastatic cancer holding a poor prognosis and a survival rate of around 10% at 2 years. Recent data reflects that at least 50% of the patients suffering from high-risk primary uveal melanoma are likely to develop a recurrence post-treatment of the primary tumor. Thus, due to the aggressive nature of this eye cancer and the availability of limited treatment options in advanced stages, there is an increased focus on the development of effective drugs to combat the disease.

Report Coverage

The Uveal Melanoma Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into uveal melanoma drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for uveal melanoma. The report includes the analysis of over 100 pipeline drugs and 50+ companies . The uveal melanoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from uveal melanoma.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to uveal melanoma.

Uveal Melanoma Drug Pipeline Outlook

Uveal melanoma (also known as choroidal melanoma) is the most commonly occurring primary intraocular malignancy in adults. In the United States, there were 3490 new cases of uveal melanoma in 2023. Although the incidence of this disease has remained nearly constant over the last few years, the main challenge of uveal melanoma lies in the metastatic stage, with survival rates of the patients dropping to only 16%.

The risk factors linked with uveal melanoma include increasing age and fair complexion. Chemotherapy and immunotherapy are common treatments for the disease. The first FDA-approved therapy for unresectable or metastatic uveal melanoma is Kimmtrak (tebentafusp-tebn). This drug works by targeting a lineage antigen (gp100) present in melanocytes and melanoma. With the rising investments in research and development of new treatments for rare forms of eye cancers, the drug pipeline for uveal melanoma is poised to lead to the market entry of promising treatment options.

Uveal Melanoma – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of unresectable melanoma drugs based on several segmentations including:

By Phase
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Drug Class
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
By Route of Administration
  • Oral
  • Parenteral
  • Others
Uveal Melanoma – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total clinical trials for uveal melanoma. There are around 26 drugs in phase II for uveal melanoma.

Uveal Melanoma – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under uveal melanoma pipeline analysis include monoclonal antibodies, peptides, polymers, small molecules, and gene therapy. The choice of treatment depends on multiple factors including the size and location of the tumor, the patient's health and age, and whether the tumor has spread to other parts of the body.

Uveal Melanoma Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for the uveal melanoma drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in uveal melanoma clinical trials:
  • Novartis Pharmaceuticals
  • TriSalus Life Sciences, Inc.
  • IDEAYA Biosciences
  • Kezar Life Sciences, Inc.
  • Fusion Pharmaceuticals Inc.
  • Xencor, Inc.
  • Immatics US, Inc.
  • Aura Biosciences
  • OncoNano Medicine, Inc.
  • Modulation Therapeutics, Inc.
Uveal Melanoma – Emerging Drugs Profile

Major drugs currently in the pipeline are as follows:

Belzupacap Sarotalocan (AU-011)

This drug is under investigation to treat patients with primary indeterminate lesions or small choroidal melanoma, a type of uveal melanoma. It is in Phase 3 of a randomized, masked, controlled study sponsored by Aura Biosciences.

Melatonin

Melatonin tablet (20 mg) is in a Phase 3 randomized trial, where its efficacy in preventing or delaying the development of metastases in around 100 patients diagnosed with primary uveal melanoma will be tested.

Darovasertib

In Phase 2 multi-center open-label study, this drug is being assessed for its treatment efficacy in primary uveal melanoma patients. Sponsored by IDEAYA Biosciences, the trial is estimated to enroll 82 participants.

Lifileucel (LN-144)

Currently, in Phase 1 of an open-label study, Lifileucel, a cryopreserved autologous tumor-infiltrating lymphocyte (TIL) therapy, is under investigation for the treatment of patients with metastatic uveal melanoma.

Reasons To Buy This Report

The Uveal Melanoma Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for uveal melanoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within uveal melanoma pipeline insights.

Key Questions Answered in the Uveal Melanoma – Pipeline Insight Report
  • What is the current landscape of uveal melanoma pipeline drugs?
  • How many companies are developing uveal melanoma drugs?
  • How many phase III and phase IV drugs are currently present in uveal melanoma pipeline drugs?
  • Which companies/institutions are leading the uveal melanoma drug development?
  • What is the efficacy and safety profile of uveal melanoma pipeline drugs?
  • What are the opportunities and challenges present in the uveal melanoma drug pipeline landscape?
  • Which company is conducting major trials for uveal melanoma drugs?
  • What geographies are covered for uveal melanoma clinical trials?
  • What are emerging trends in uveal melanoma clinical trials?
Related Reports

Global Intraocular Melanoma Treatment Market

Global Cancer Therapeutics Market

Global Clinical Trials Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Uveal Melanoma
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Types of Uveal Melanoma
3.5 Diagnosis
3.6 Treatment
4 Patient Profile: Uveal Melanoma
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Uveal Melanoma: Epidemiology Snapshot
5.1 Uveal Melanoma Incidence by Key Markets
5.2 Uveal Melanoma – Patients Seeking Treatment in Key Markets
6 Uveal Melanoma: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Uveal Melanoma: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Uveal Melanoma, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Uveal Melanoma Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Uveal Melanoma Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Tebentafusp
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Belzupacap Sarotalocan
10.2.3 Melatonin
10.2.4 Other Drugs
11 Uveal Melanoma Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Darovasertib
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 BVD-523
11.2.3 Other Drugs
12 Uveal Melanoma Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Lifileucel (LN-144)
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 APG-115+pembrolizumab
12.2.3 Other Drugs
13 Uveal Melanoma Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.3 Other Drugs
14 Uveal Melanoma, Key Drug Pipeline Companies
14.1 Novartis Pharmaceuticals
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 TriSalus Life Sciences, Inc.
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 IDEAYA Biosciences
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Kezar Life Sciences, Inc.
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Fusion Pharmaceuticals Inc.
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Xencor, Inc.
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 Immatics US, Inc.
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
14.8 Aura Biosciences
14.8.1 Company Snapshot
14.8.2 Pipeline Product Portfolio
14.8.3 Financial Analysis
14.8.4 Recent News and Developments
14.9 OncoNano Medicine, Inc.
14.9.1 Company Snapshot
14.9.2 Pipeline Product Portfolio
14.9.3 Financial Analysis
14.9.4 Recent News and Developments
14.10 Modulation Therapeutics, Inc.
14.10.1 Company Snapshot
14.10.2 Pipeline Product Portfolio
14.10.3 Financial Analysis
14.10.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us